Tafamidis for treating transthyretin amyloidosis with cardiomyopathy (TA696)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 12 May 2021
Tafamidis for treating transthyretin amyloidosis with cardiomyopathy [ID6327]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 19 June 2024
Acoramidis for treating transthyretin-mediated amyloidosis cardiomyopathy [ID6354]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Eplontersen for treating transthyretin-related amyloidosis cardiomyopathy TSID 12015Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC